Markets will come.The trial version is still running oversease, and with good results at that. Generating revenue should be easy once they hit the US market. With or without Obama care there will still be some sort of increase. Maybe not the 5$ price target analysts have predicted, but still a large increase compared to current trial incomes. Keep in mind there has not been any of this research or medicine on US soil. Every bit of study has been done abroad. When Phase lll is done, and this medicine finally has a buyer, say hello to a strong and profitable SDI.